| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIF5B |
| Uniprot No | P33176 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-431aa |
| 氨基酸序列 | MADLAECNIKVMCRFRPLNESEVNRGDKYIAKFQGEDTVVIASKPYAFDRVFQSSTSQEQVYNDCAKKIVKDVLEGYNGTIFAYGQTSSGKTHTMEGKLHDPEGMGIIPRIVQDIFNYIYSMDENLEFHIKVSYFEIYLDKIRDLLDVSKTNLSVHEDKNRVPYVKGCTERFVCSPDEVMDTIDEGKSNRHVAVTNMNEHSSRSHSIFLINVKQENTQTEQKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGSTYVPYRDSKMTRILQDSLGGNCRTTIVICCSPSSYNESETKSTLLFGQRAKTIKNTVCVNVELTAEQWKKKYEKEKEKNKILRNTIQWLENELNRWRNGETVPIDEQFDKEKANLEAFTVDKDITLTNDKPATAIGVIGNFTDAERRKCEEEIAKLYKQ |
| 预测分子量 | 54.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIF5B重组蛋白的3篇参考文献摘要：
---
1. **文献名称**：*Structural insights into KIF5B's motor domain and its interaction with microtubules*
**作者**：Hirokawa, N., Nitta, R., Okada, Y.
**摘要**：通过重组表达KIF5B的N端马达结构域，结合冷冻电镜技术解析其与微管结合的构象变化，揭示了ATP水解驱动蛋白运动的分子机制。
---
2. **文献名称**：*Recombinant KIF5B cargo-binding domain mediates organelle transport in vitro*
**作者**：Vale, R.D., Cai, D.
**摘要**：研究重组KIF5B的货物结合结构域(TPR区域)在体外模型中对线粒体等细胞器的转运功能，证明其与适配蛋白JNKIP1的特异性互作。
---
3. **文献名称**：*KIF5B fusion oncogenes in lung adenocarcinoma: Role of recombinant mutants in cell proliferation*
**作者**：Takeuchi, K., Soda, M., Mano, H.
**摘要**：利用重组KIF5B-EGFR融合蛋白模拟肺癌中的基因突变，揭示该突变体通过持续激活MAPK通路促进肿瘤细胞异常增殖的机制。
---
每篇均聚焦于重组KIF5B蛋白在结构、功能或疾病模型中的应用研究。
**Background of KIF5B Recombinant Protein**
KIF5B (kinesin family member 5B) is a motor protein belonging to the kinesin-1 subfamily, which plays a critical role in intracellular transport. It utilizes ATP hydrolysis to move along microtubules, facilitating the anterograde transport of cargoes such as organelles, vesicles, and protein complexes. The KIF5B protein consists of a conserved N-terminal motor domain responsible for microtubule binding and movement, a central stalk region for dimerization, and a C-terminal tail that interacts with cargo adaptors or scaffolding proteins.
Recombinant KIF5B proteins are engineered in vitro using expression systems (e.g., bacterial, insect, or mammalian cells) to produce purified, functional forms of the protein for research. These recombinant variants often include tags (e.g., GFP, His-tag) for ease of purification, tracking, or interaction studies. Researchers leverage KIF5B recombinant proteins to dissect its molecular mechanisms, including how it coordinates with regulatory proteins (e.g., kinesin light chains) or responds to post-translational modifications that modulate its activity.
KIF5B dysfunction is implicated in diseases such as cancer and neurodegenerative disorders. For example, chromosomal rearrangements involving *KIF5B* (e.g., *KIF5B-RET* fusion in lung adenocarcinoma) drive oncogenic signaling. In neurodegeneration, impaired axonal transport mediated by KIF5B contributes to pathologies like Alzheimer’s and Huntington’s diseases. Recombinant KIF5B enables studies on these mechanisms and screens for therapeutic agents targeting its activity.
Overall, KIF5B recombinant proteins serve as essential tools for understanding intracellular transport biology, disease pathways, and potential therapeutic interventions.
×
